ICH Q1A-aligned stability programmes for finished drug products, APIs and dietary supplements. We design the protocol, run the study at controlled conditions, manage pull-points, and deliver dossier-ready reports — at any phase from preclinical through commercial.
Long-term stability (25 °C / 60% RH; 30 °C / 65% RH)
Intermediate stability (30 °C / 65% RH)
Accelerated stability (40 °C / 75% RH)
Refrigerated and frozen storage (5 °C, -20 °C, -80 °C)
Photostability per ICH Q1B
Stress / forced-degradation studies (acid, base, oxidation, heat, light)
In-use and in-package stability
Bracketing and matrixing for cost-efficient programmes
Temperature- and humidity-controlled walk-in and reach-in chambers with continuous monitoring and excursion alarms.
ICH Q1B Option 2 lighting (cool-white + near-UV) with quinine actinometry.
Validated stability-indicating HPLC / UPLC, dissolution, microbial limits and content tests at every pull.
Pull-by-pull data tables, plots, trend analysis and shelf-life recommendation per ICH Q1E.
Methods, documentation and acceptance criteria are designed to align with the standards below. This describes design intent — formal accreditations are listed on the About page.
Stability protocol (ICH-formatted) approved before study start
Per-pull CoA at every time point
Stability summary report at study end with shelf-life recommendation
Trending plots (assay, related substances, dissolution, microbial)
Investigation reports for OOS / OOT pulls
Annual stability commitment management for marketed products
Send a short scope and we'll come back with a quote and indicative timeline within one working day.